TABLE 2.
Stem cells clinical trials for the discussed Alzheimer disease that are registered with ClinicalTrials.gov and signified as “not yet recruiting”, “recruiting”, “enrolling by invitation”, “active not recruiting”, “completed”, or “unknown status” (as of June 2022).
| Row | Status | Study title | Stem cell type of intervention | Phase | Country |
|---|---|---|---|---|---|
| 1 | Recruiting | Allogeneic human mesenchymal stem cells for Alzheimer’s disease | Human mesenchymal stem cells | 2 | United States |
| 2 | Active not recruiting | Alzheimer’s disease stem cells multiple infusions | Allogeneic hMSC | 1 | United States |
| 3 | Unknown | Safety and efficiency of umbilical cord-derived mesenchymal stem cells (UC-MSC) in patients with Alzheimer’s disease | Human umbilical cord derived MSC | 1/2 | China |
| 4 | Completed | Safety and exploratory efficacy study of NEUROSTEM® versus placebo in patients with Alzheimer’s disease | Human umbilical cord blood derived mesenchymal stem cells | 1/2 | Korea |
| 5 | Completed | The safety and the efficacy evaluation of NEUROSTEM®-AD in patients with Alzheimer’s disease | Human umbilical cord blood derived-mesenchymal stem cells | 1 | Korea |
| 6 | Completed | Lomecel-B infusion versus placebo in patients with Alzheimer’s disease | Longeveron mesenchymal stem cells | 1 | United States |
| 7 | Recruiting | The safety and the efficacy evaluation of allogenic adipose MSC-exos in patients with Alzheimer’s disease | Allogenic adipose MSC-exos | 1/2 | China |
| 8 | Not yet recruiting | Study to evaluate the safety and efficacy of AstroStem in treatment of Alzheimer’s disease | AstroStem | 2 | United States |
| 9 | Completed | A study to evaluate the safety and efficacy of AstroStem in treatment of Alzheimer’s disease | AstroStem | 1/2 | United States |
| 10 | Not yet recruiting | Exploratory efficacy study of NEUROSTEM® in subjects who control group of NEUROSTEM® | Human umbilical cord blood derived mesenchymal stem cells | Not applicable | Korea |
| 11 | Recruiting | Follow-up study of safety and efficacy in subjects Who completed NEUROSTEM® phase-I/IIa clinical trial | Human umbilical cord blood derived mesenchymal stem cells | 1/2 | Korea |
| 12 | Recruiting | Alzheimer’s autism and cognitive impairment stem cell treatment study | Bone marrow stem cell (BMSC) | Not applicable | United States |
| 13 | Not yet recruiting | Autologous stem/stromal cells in neurological disorders and disease | Autologous adipose stem cells | Not applicable | United States |